SEC Form 4 · accession 0001209191-18-020441
Arcadia Biosciences, Inc. · RKDA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eric J. Rey
Director
Period of report
Mar 14, 2018
Accepted (ET)
Mar 16, 2018 · 8:11 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001469443
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 14, 2018 | M | 21,005 | $21.60 | A | 28,340 | D | |
| Common StockF2 | Mar 14, 2018 | S | 21,005 | $45.209 | D | 7,335 | D | |
| Common Stock | Mar 15, 2018 | M | 250 | $44.80 | A | 7,585 | D | |
| Common Stock | Mar 15, 2018 | S | 250 | $60.00 | D | 7,335 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F3 | $21.60 | Mar 14, 2018 | M | 21,005 | D | — | Jun 30, 2018 | Common Stock | 21,005 | 35,969 | D |
| Employee Stock Option (right to buy)F3 | $44.88 | Mar 15, 2018 | M | 250 | D | — | Nov 1, 2019 | Common Stock | 250 | 35,719 | D |
Explanation of responses
- F1The security transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Stock Trading Plan adopted by the Reporting Person effective June 6, 2017.
- F2This transaction was executed in multiple trades at prices ranging from $38.00 to $49.80. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3The option is fully exercisable as of the date hereof.